Exelixis, Inc. (EXEL)

NASDAQ: EXEL · IEX Real-Time Price · USD
18.48
+0.15 (0.82%)
At close: Mar 24, 2023, 4:00 PM
18.45
-0.03 (-0.16%)
After-hours: Mar 24, 2023, 7:17 PM EDT
0.82%
Market Cap 5.99B
Revenue (ttm) 1.61B
Net Income (ttm) 182.28M
Shares Out 324.09M
EPS (ttm) 0.56
PE Ratio 33.00
Forward PE 10.58
Dividend n/a
Ex-Dividend Date n/a
Volume 8,617,582
Open 18.27
Previous Close 18.33
Day's Range 17.90 - 18.52
52-Week Range 14.87 - 23.40
Beta 0.69
Analysts Buy
Price Target 25.69 (+39.02%)
Earnings Date May 9, 2023

About EXEL

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, inclu... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 7, 2000
Employees 954
Stock Exchange NASDAQ
Ticker Symbol EXEL
Full Company Profile

Financial Performance

In 2022, Exelixis's revenue was $1.61 billion, an increase of 12.27% compared to the previous year's $1.43 billion. Earnings were $182.28 million, a decrease of -21.11%.

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is $25.69, which is an increase of 39.02% from the latest price.

Price Target
$25.69
(39.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Exelixis Announces $550 Million Share Repurchase Program

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company's Board of Directors has authorized the repurchase of up to $550 million of the company's common stock ...

4 days ago - Business Wire

Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday, M...

1 week ago - Business Wire

Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal

Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).

2 weeks ago - Zacks Investment Research

Exelexis stock falls as kidney cancer drug trial fails

Exelixis Inc. EXEL, -1.66% shares fell in the extended session Thursday after the biotech drug maker said a late-stage clinical trial of its kidney cancer drug treatment did not meet its endpoint. Exe...

3 weeks ago - Market Watch

Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS).

3 weeks ago - Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences i...

3 weeks ago - Business Wire

Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805

Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.

1 month ago - Zacks Investment Research

Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

ALAMEDA, Calif. & ROTTERDAM, The Netherlands--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the U.S. Food and Drug Administration (FDA) has cleared Sai...

1 month ago - Business Wire

Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx

Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.

1 month ago - Zacks Investment Research

Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics

The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street esti...

1 month ago - Zacks Investment Research

Exelixis (EXEL) Reports Q4 Loss, Tops Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 40% and 1.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year of 2022 and provided an update on progress toward achieving key co...

1 month ago - Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences...

1 month ago - Business Wire

Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 7, 2023 after the m...

2 months ago - Business Wire

Exelixis Announces Update on Patent Litigation with MSN Laboratories

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) v. MSN Laboratories Private Limited et al. (MSN), Action No. 19-2017 (Co...

2 months ago - Business Wire

7 Biotech Stocks That Will Make You Rich in 10 Years

If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they'r...

2 months ago - InvestorPlace

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

TOKYO , Jan. 10, 2023 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary sit...

2 months ago - PRNewsWire

Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results

Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.

2 months ago - Zacks Investment Research

Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2022, provided financial guidance for...

2 months ago - Business Wire

Four Undervalued Healthcare Stocks for 2023

These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.

Other symbols: INVAPFEREGN
2 months ago - MarketBeat

Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the ...

Other symbols: STOK
2 months ago - Business Wire

Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 —  Presentation to be webcast on www.exelixis.com  —

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overvi...

2 months ago - Business Wire

7 Undervalued Biotech Stocks to Buy Before They Boom

Although the sector can be quite volatile, these undervalued biotech stocks to buy offer a compelling narrative for investors. Fundamentally, the underlying narrative focuses on addressing the critica...

3 months ago - InvestorPlace

Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-304, a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus s...

3 months ago - Business Wire